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Abstract Background: Levofloxacin 0.5% ophthalmic solution is an antibacterial for-
mulation, which was approved and marketed for the treatment of ocular
infections in Japan in 2000.
Objective: This study was designed to investigate the safety and efficacy of
levofloxacin 0.5% ophthalmic solution in patients who received treatment for
external ocular bacterial infections in regular clinical practice.
Methods: Patients were recruited from more than 800 medical facilities in
Japan, in accordance with Japanese Ministry of Health, Labour and Welfare
ordinance guidelines. They were followed during three distinct time periods:
April 2000 to December 2001, January 2002 to June 2003, and July 2003 to
December 2004.
Results: Information from 6760 patients receiving levofloxacin for the treat-
ment of a variety of ocular infections was collected. Levofloxacin was well
tolerated: adverse drug reactions (ADRs) were reported in 42 of 6686 patients
(0.63%), with no serious ADRs reported. The most commonly reported
ADRs were ocular disorders such as blepharitis, eye irritation, and punctate
keratitis. The incidence of ADRs did not differ significantly with age, but it
was significantly higher in females (0.82%) than in males (0.36%; p= 0.028).
A clinical response was observed in 95.5% of patients receiving levofloxacin,
with no difference in response between the three time periods. The rate of
response to levofloxacin by bacterial disease ranged from 97.4% in keratitis to
88.3% in dacryocystitis. The rate was lower in patients with dacryocystitis,
elderly patients, patients with a long duration of illness, and relapsing cases
(all p < 0.001).
Conclusion: This post-marketing surveillance of levofloxacin, conducted over
4 years, confirms the safety and efficacy of levofloxacin in regular clinical use
and highlights that levofloxacin is a promising treatment for a variety of
external ocular bacterial infections.
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Introduction
Levofloxacin 0.5% ophthalmic solution (Cravit
ophthalmic solution 0.5%; Santen Pharmaceutical
Co., Ltd., Osaka, Japan) is an antibacterial eye drop
formulation, which contains the active ingredient
levofloxacin, a synthetic antimicrobial agent of the
fluoroquinolone family.[1] Fluoroquinolones are
known to exert antimicrobial activity through in-
hibition of DNA gyrase, an enzyme involved in
bacterial DNA synthesis. They have been used
extensively for the treatment of bacterial infections
in clinical practice because of their potent activity
against a wide range of Gram-positive and
Gram-negative microbes. Furthermore, topical
fluoroquinolones, such as ophthalmic solutions
containing norfloxacin or ofloxacin, have been
widely prescribed for the treatment of external
ocular bacterial infections.[2]
Levofloxacin, an L-isomer of ofloxacin, has
two times greater antimicrobial activity than
ofloxacin[3] and has high water solubility at a
neutral pH, allowing for the preparation of high-
concentration formulations. Clinical trials of
levofloxacin 0.5% ophthalmic solution revealed
that levofloxacin ophthalmic solution was supe-
rior to ofloxacin ophthalmic solution.[4-7] As a
result, levofloxacin 0.5% ophthalmic solution
was approved and marketed in Japan in 2000 for
the treatment of bacterial conjunctivitis or other
external ocular infections and for perioperative
use during ocular surgery.[1] It is approved for the
treatment of bacterial conjunctivitis in the US
(Quixin)[8] and is also approved in several
European countries for the treatment of ocular
infections (Oftaquix).[9]
Japanese regulatory authority policy required
monitoring of the safety and efficacy of levo-
floxacin 0.5% ophthalmic solution for the treat-
ment of ocular bacterial infections for up to
6 years after its approval. In accordance with this,
surveillance was conducted on the use of levo-
floxacin 0.5% ophthalmic solution, initiated im-
mediately after levofloxacin was launched on the
market. In this article, we present the results of
this post-marketing surveillance of levofloxacin
0.5% ophthalmic solution used in everyday clin-
ical practice in a large patient population.
Methods
Patients
This survey was designed to investigate the
safety and efficacy of levofloxacin 0.5% oph-
thalmic solution in patients who received treat-
ment for external ocular bacterial infections in
regular clinical practice. Patients who had pre-
viously received levofloxacin 0.5% ophthalmic
solution were excluded. Patients were recruited
from more than 800 medical facilities in Japan,
and treatment was based on the decision of the
physician. The study protocol was set up in ac-
cordance with Ministry of Health, Labour and
Welfare ordinance guidelines,[10,11] and a con-
tract with all medical facilities participating in
this study was constructed. Written informed
consent was not obtained, as Japanese law does
not require informed consent for this type of non-
interventional observational study.
Study Design
To eliminate bias in case extraction, a con-
tinuous investigation method was adopted,
where patients were registered in chronological
order depending on the time when treatment
was initiated. Of these patients, those re-visiting
the same medical facility were formally enrolled
in the survey in chronological order (depend-
ing on the date of the first treatment with
levofloxacin 0.5% ophthalmic solution) and
entered into the case report form (CRF). The
end of enrollment at each medical facility oc-
curred at the time when the number of patients
reached the number specified in that facility’s
contract.
The influence of the development of drug-
resistant bacterial strains on the efficacy of levo-
floxacin over time was also investigated, by con-
ducting the survey in three distinct time periods:
from April 2000 through to December 2001 (the
first period), from January 2002 through to June
2003 (the second period), and from July 2003
through toDecember 2004 (the third period). The
targeted number of patients was 2000 for each
time period.
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Survey Design and Analysis
Survey Items
The survey collected data pertaining to the
background characteristics and demographics of
each patient, the dosage and treatment duration
of levofloxacin 0.5% ophthalmic solution, con-
comitant drugs and therapies, clinical symptoms
of infection, adverse events associated with
treatment, overall improvement, and bacterio-
logical test data (if assessed).
Safety
Adverse events were defined as any medically
unfavorable event taking place during or after
treatment with levofloxacin 0.5% ophthalmic
solution. Adverse drug reactions (ADRs) were
considered treatment related if a causal relation-
ship with levofloxacin 0.5% ophthalmic solution
could not be ruled out.
Efficacy
The efficacy of levofloxacin 0.5% ophthalmic
solutionwas assessed by the physicians in charge of
each medical center, using a three-category scale.
The overall change was rated as ‘improved’, ‘un-
changed’, or ‘worsened’. Clinical response rates
were assessed, using the following calculation:
Response rate (%) =
Total no. of patients included
in efficacy evaluation
× 100No. of improved patients
Study Populations and Statistical Analysis
The safety analysis population included all
patients who completed a CRF, excluding cases
that violated the study protocol (including vio-
lation of the continuous investigation method,
redundantly enrolled patients, etc.). The efficacy
analysis population included all CRFs that were
included in the safety population, excluding cases
that received levofloxacin 0.5% ophthalmic solu-
tion for diseases other than external ocular bac-
terial infections and cases where the physician
was unable to judge the overall improvement of
the disease to treatment. The Pearson’s w2 test
and the Cochran-Armitage test were used for
analysis of safety and efficacy data. A p-value of
<0.05 (two-tailed) was regarded as statistically
significant. The Medical Dictionary for Regu-
latory Activities/Japanese Edition (MedDRA/J)
version 8.1 was employed for classifying ADRs.
Results
Patient Recruitment and Populations
During the three periods of surveillance, CRFs
for 6760 patients were collected from 808 medical
centers, including ophthalmology departments
at 14 university hospitals, 22 national/public hos-
pitals, 20 quasi-public hospitals, and 62 other
hospitals, as well as 690 ophthalmic general prac-
titioners. CRFs were completed for 2399 patients
during the first time period (from 314 medical
centers), 2133 patients during the second period
(293 medical centers), and 2228 patients during the
third period (290 medical centers). Of these 6760
cases, 74 cases were excluded from the safety
evaluation, with the remaining 6686 cases being
included in the safety analysis. Of these, 757 cases
were excluded from the efficacy evaluation, with
the remaining 5929 cases being included in the
efficacy analysis (figure 1).
Treatment Duration
The median dosing period, which was assumed
to be the duration of treatment required to cure
the disease, was 8 days for hordeolum, keratitis,
and corneal ulcers; 9 days for conjunctivitis; and
10 days for blepharitis and tarsadenitis. In com-
parison, it was 29 days for dacryocystitis (figure 2).
Levofloxacin 0.5% ophthalmic solution was ad-
ministered 3–4 times daily in patients with ble-
pharitis, dacryocystitis, hordeolum, conjunctivitis,
and tarsadenitis; 4 times daily in patients with
keratitis; and 4–6 times daily in patients with cor-
neal ulcers (table I).
Safety
Adverse Drug Reactions
Of the 6686 patients included in the safety
evaluation, 46 ADRs were reported in 42 patients.
The overall incidence of ADRs was 0.63%. The
most commonly reported ADRs were ocular dis-
orders such as blepharitis (7 cases, 0.10%), eye
irritation (6 cases, 0.09%) and punctate keratitis
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(5 cases, 0.07%). None of the 46 ADRs reported
were considered serious (table II).
Adverse Drug Reactions According to Patient
Demographics and Dosing Frequency of
Levofloxacin
Table III lists the ADRs reported during the
post-marketing surveillance of levofloxacin 0.5%
ophthalmic solution, according to patient demo-
graphics and the dosing frequency of levo-
floxacin. Of interest, the incidence of ADRs was
significantly higher in females (0.82%) than in
males (0.36%; p = 0.028), and eye irritation and
eye pruritus were reported only in females. Of the
3904 women surveyed, seven were pregnant; none
reported any adverse events with administration
of levofloxacin 0.5% ophthalmic solution. How-
ever, no information pertaining to the effects of
levofloxacin 0.5% ophthalmic solution on labor
or on the health of the newborn was collected.
There was no correlation between the age of
the patient and the incidence of ADRs (table III).
In patients aged <15 years, the incidence of ADRs
was 0.32%, which was no higher than those re-
ported in patients aged ‡15 and <65 years or
in patients aged ‡65 years (0.62% and 0.81%, re-
spectively). ADRs were found in four children:
punctate keratitis (1 case), eye pruritus (1 case),
dermatitis contact (1 case), and urticaria (1 case).
No ADRs were reported in patients younger than
1 year old.
As for the dosing frequency of levofloxacin,
the incidence of ADRs did not differ signi-
ficantly depending on the mean daily frequency




A clinical response was observed in 95.5% of
the 5929 patients included in the efficacy popu-
lation. Response rates did not differ significantly
between the three time periods of the survey
(p = 0.099, w2 test). Clinical response was ob-
served in 94.7% of patients in the first time period,
95.9% of patients in the second time period, and
95.9% of patients in the third time period.
Response Rates According to Disease Diagnosis
The rates of clinical response to treatment with
levofloxacin 0.5% ophthalmic solution are sum-
marized in table IV, according to the type of
external ocular bacterial infection that was
reported. Cases where patients were diagnosed
with two or more diseases were counted in each
disease group. Response rates were similar for
most types of external ocular infection; however,
the response rate was 88.3% in patients who were
diagnosed with dacryocystitis, which was sig-
nificantly lower than the response rate observed
in patients who were diagnosed with any other
type of ocular infection (95.8%; p < 0.001).
The clinical response rates in patients with hor-
deolum and conjunctivitis differed significantly
between the three investigational time periods
(p= 0.027 and p= 0.019, respectively). However,
these response rates did not decrease over time.
Case report form retrieved
n = 6760
Excluded from safety evaluation
n = 74
Reasons for exclusion:
Violation of study protocol (n = 73)
Levofloxacin not received (n = 1)
Included in safety evaluation
n = 6686
Included in efficacy evaluation
n = 5929
Excluded from efficacy evaluation
n = 757
Reasons for exclusion:
Other disease (n = 714)1
Unable to judge response (n = 43)
1    These patients received levofloxacin 0.5% ophthalmic solution
for a disease other than external ocular bacterial infection.
Fig. 1. Patient populations included in the safety and efficacy
analyses of levofloxacin 0.5% ophthalmic solution.
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Response Rates According to Type of Bacteria
Isolated
Of the 5929 patients included in the efficacy
evaluation, 1814 patients underwent a bacterio-
logical test at the start of treatment with levo-
floxacin 0.5% ophthalmic solution. Bacteria were
isolated from 1152 patients, and the response rate
of these patients was analyzed according to the
type of bacteria that was isolated (table V). Cases
where two or more strains of bacteria were iso-
lated were counted in each bacterial group. The
response rates were around 90% for major bac-
terial strains of external ocular infections, such as
Staphylococcus spp., Streptococcus spp., Strep-
tococcus pneumoniae, Corynebacterium spp., and
Haemophilus influenzae. When the response rates
for each bacterial strain were compared between
the three time periods, there was no strain whose
response rate differed significantly between the
time periods.
Response Rates According to Background
Demographics and Characteristics
Table VI shows the efficacy of levofloxacin
0.5% ophthalmic solution, according to back-
ground demographics and characteristics. Age,
duration of illness, and disease history all sig-
nificantly affected the response to treatment (all
p < 0.001). As age advanced, response rates were
lower. Furthermore, lower clinical response rates
were reported in patients who had a longer du-
ration of ocular disease or who had relapsed.
Discussion
Clinical trials for new-drug applications are
generally carried out in controlled environments
with limitations set on various factors, including
the number of enrolled patients, the age of the
patients, the presence of disease complications,
and the use of concomitant drugs. For this rea-
son, the information provided by clinical trials
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Blepharitis (n = 269)
Corneal ulcers (n = 466)
Dacryocystitis (n = 234)
Hordeolum (n = 954)
Conjunctivitis (n = 3290)
Tarsadenitis (n = 139)
Keratitis (n = 709)
Treatment period (days)
Fig. 2. Median duration of treatment with levofloxacin 0.5% ophthalmic solution in responders, according to ocular disease type. The gray
data-point markers indicate median values, and the horizontal data lines indicate 25th–75th percentile ranges.
Table I. Median daily dosing frequency of levofloxacin 0.5%
ophthalmic solution, according to disease
Disease N Median daily dosing frequency
[25th–75th percentile]
Blepharitis 269 4.00 [3.00–4.00]
Dacryocystitis 230 4.00 [3.00–4.00]
Hordeolum 954 4.00 [3.00–4.00]
Conjunctivitis 3 289 4.00 [3.00–4.00]
Tarsadenitis 139 4.00 [3.00–4.00]
Keratitis 708 4.00 [4.00–4.00]
Corneal ulcers 466 4.64 [4.00–6.00]
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cannot always predict the efficacy and safety of a
drug in the real-world setting, and it is important
to collect and evaluate further data on safety and
efficacy in the post-marketing setting. This study
was undertaken to survey the post-marketing use,
safety, and efficacy of levofloxacin 0.5% oph-
thalmic solution for the treatment of external
ocular bacterial infections over three distinct time
periods in Japan.
Our study suggested that levofloxacin 0.5%
ophthalmic solution is well tolerated in a large pa-
tient population. The proportion of patients with
ADRs was less than 1%. This is comparable to the
reported incidence of ADRs associated with other
fluoroquinolone ophthalmic solutions (ofloxacin,
lomefloxacin, and norfloxacin) in post-marketing
surveillance studies in Japan.[12-14] Furthermore, in
our study, no serious ADRs were reported. ADRs
were reported more frequently in females than in
males. However, this finding does not seem to be
specific to levofloxacin 0.5% ophthalmic solution.
A post-marketing surveillance report of another
ophthalmic solution used for the treatment of al-
lergic conjunctivitis also demonstrated a higher
incidence of ADRs, such as eye irritation, in
females.[15] In the pre-marketing clinical trials of
levofloxacin 0.5% ophthalmic solution, there were
insufficient data to determine the safety and
efficacy of treatment in the pediatric setting, as
only 16 children received levofloxacin ophthalmic
solution (including ones who received the 0.3%
Table II. Adverse drug reactions associated with levofloxacin 0.5%
ophthalmic solution reported in the 804 facilities surveyed (safety
population: N = 6686)
ADR n [%]
No. of patients reporting any ADR 42 [0.63]
No. of ADRs reported 46
Nervous system disorders 1 [0.01]
Numbness of fingers 1 [0.01]
Eye disorders 39 [0.58]
Corneal erosion 2 [0.03]
Keratitis 4 [0.06]
Corneal epithelium disorder 1 [0.01]
Punctate keratitis 5 [0.07]
Eye pruritus 3 [0.04]
Eyelids pruritus 1 [0.01]
Foreign body sensation in eyes 1 [0.01]
Eye irritation 6 [0.09]
Eye pain 2 [0.03]
Ocular discomfort 1 [0.01]
Blepharitis 7 [0.10]
Eyelid edema 2 [0.03]
Conjunctivitis 2 [0.03]
Conjunctival hyperemia 2 [0.03]
Episcleritis 1 [0.01]
Lacrimation increased 2 [0.03]
Gastrointestinal disorders 1 [0.01]
Oral numbness 1 [0.01]
Skin and subcutaneous tissue disorders 2 [0.03]
Dermatitis contact 1 [0.01]
Urticaria 1 [0.01]
ADR = adverse drug reaction.
Table III. Adverse drug reactions associated with levofloxacin 0.5%
ophthalmic solution, according to patient demographics and fre-
quency of levofloxacin dosing
Variable N ADR (n [%]) p-Value
Sex 0.028a
Male 2 782 10 [0.36]
Female 3 904 32 [0.82]
Age 0.079b,c
<15 years 1 259 4 [0.32]
<4 weeks 20 0
‡4 weeks and <1 year 187 0
‡1 and <7 years 666 3 [0.45]
‡7 and <15 years 386 1 [0.26]
‡15 and <65 years 3 212 20 [0.62]




<3 doses 80 0
3 doses 1 792 12 [0.67]
4 doses 3 840 22 [0.57]
5 doses 411 4 [0.97]
6 doses 440 3 [0.68]
7 doses 20 0
‡8 doses 96 0
Unknown 7 1 [14.29]
a p-Values were assessed by Pearson’s w2 test. Cases with
unknown information were excluded from this test.
b p-Values were assessed by the Cochran-Armitage test. Cases
with unknown information were excluded from this test.
c p-Value for age <15 years versus ‡15 years and for age
<65 years versus ‡65 years.
ADR = adverse drug reaction.
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preparation). This study collected data on the use of
levofloxacin in 1259 children and showed that lev-
ofloxacin 0.5% ophthalmic solution can be used
safely in children. ADRs were reported in only
0.32% of the children, whichwas not higher than the
rates reported in patients in the other age groups.
This study also suggested that levofloxacin
0.5% ophthalmic solution is effective in everyday
clinical practice. The clinical response rate of ex-
ternal ocular bacterial infections was high, with
95.5% of all patients included in the efficacy
analysis reporting a clinical response. In the
subgroup analysis, the rate was lower in patients
with dacryocystitis, elderly patients, patients with
a long duration of illness, and relapsing cases.
Dacryocystitis is typically a difficult disease to
treat, and it appears that a longer duration of
illness or a relapse of illness is also associated with










Blepharitis 96.4 [269/279] 95.7 [89/93] 95.3 [81/85] 98.0 [99/101] 0.548
Dacryocystitis 88.3 [234/265] 89.5 [128/143] 88.9 [64/72] 84.0 [42/50] 0.570
Hordeolum 94.2 [954/1013] 93.4 [309/331] 92.2 [309/335] 96.8 [336/347] 0.027
Conjunctivitis 95.5 [3292/3446] 94.4 [1208/1279] 96.9 [1017/1050] 95.5 [1067/1117] 0.019
Tarsadenitis 95.2 [139/146] 93.8 [60/64] 97.8 [45/46] 94.4 [34/36] 0.596
Keratitisb 97.4 [1159/1190] 97.2 [346/356] 97.5 [396/406] 97.4 [417/428] 0.954
a p-Values were assessed by Pearson’s w2 test and are for the first period versus the second period versus the third period.
b Including corneal ulcers.










Staphylococcus spp. 93.5 [561/600] 92.7 [316/341] 96.5 [137/142] 92.3 [108/117] 0.254
Streptococcus spp. 88.5 [77/87] 84.9 [45/53] 95.2 [20/21] 92.3 [12/13] 0.407
Streptococcus pneumoniae 95.9 [93/97] 98.3 [58/59] 89.5 [17/19] 94.7 [18/19] 0.233
Enterococcus spp. 100 [22/22] 100 [13/13] 100 [3/3] 100 [6/6] NA
Micrococcus spp. 100 [2/2] 100 [1/1] ND 100 [1/1] NA
Moraxella spp. 96.7 [29/30] 100 [11/11] 100 [11/11] 87.5 [7/8] 0.241
Corynebacterium spp. 93.5 [186/199] 93.9 [124/132] 93.8 [30/32] 91.4 [32/35] 0.864
Klebsiella spp. 100 [7/7] 100 [3/3] 100 [3/3] 100 [1/1] NA
Enterobacter spp. 100 [10/10] 100 [6/6] ND 100 [4/4] NA
Serratia spp. 100 [30/30] 100 [18/18] 100 [5/5] 100 [7/7] NA
Proteus spp. 100 [4/4] 100 [1/1] 100 [2/2] 100 [1/1] NA
Morganella morganii 85.7 [6/7] 100 [3/3] 50.0 [1/2] 100 [2/2] 0.232
Haemophilus influenzae 98.9 [181/183] 98.8 [81/82] 97.8 [45/46] 100 [55/55] 0.572
Haemophilus aegyptius
(Koch-Weeks bacillus)
100 [1/1] 100 [1/1] ND ND NA
Pseudomonas spp. 100 [20/20] 100 [12/12] 100 [4/4] 100 [4/4] NA
Pseudomonas aeruginosa 80.8 [21/26] 83.3 [15/18] 80.0 [4/5] 66.7 [2/3] 0.793
Stenotrophomonas
(Xanthomonas) maltophilia
71.4 [5/7] 66.7 [4/6] ND 100 [1/1] 1.000
Acinetobacter spp. 82.8 [24/29] 83.3 [15/18] 80.0 [4/5] 83.3 [5/6] 0.984
Propionibacterium acnes 85.7 [6/7] 83.3 [5/6] ND 100 [1/1] 1.000
a p-Values were assessed by Pearson’s w2 test and are for the first period versus the second period versus the third period.
NA= not applicable; ND =no data.
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lower efficacy. Furthermore, the low response
rate observed in this study in elderly patients
seems to be attributable to a high percentage of
patients with dacryocystitis, cases with a long
duration of illness, and relapsing cases.
The clinical response observed with levo-
floxacin 0.5% ophthalmic solution was not re-
duced over time or when analyzed according to
the type of ocular disease or the type of bacterium
involved. In parallel with this post-marketing
surveillance, a drug sensitivity test was conducted
to evaluate the susceptibility of fresh clinically
isolated bacterial strains (derived from patients
with ocular infection) to levofloxacin and other
drugs.[16-18] This test indicated that the bacterial
strains associated with ocular infections did not
tend to develop resistance to levofloxacin over
time. However, it is important to monitor for the
possible development of drug-resistant strains in
the future, because bacterial strains with minimal
inhibitory concentrations higher than 128 mg/mL
were found among methicillin-resistant Staphylo-
coccus aureus and Corynebacterium spp. soon
after the marketing of levofloxacin 0.5% oph-
thalmic solution, and there was a report of cases
developing infection with levofloxacin-resistant
Corynebacterium spp. via the sutures.[19]
Treatment with levofloxacin 0.5% ophthalmic
solution was completed within 10 days in 50% of
the cases. This is ideal, because the disappearance
of major symptoms within 2 weeks of treatment is
one of the criteria used to determine a clinical
response according to the Japanese criteria for
evaluation of antimicrobial ophthalmic solu-
tions.[20] However, the treatment period was
longer and the response rate was lower in patients
with dacryocystitis than in patients with other
infections. As discussed above, treatment of da-
cryocystitis with an ophthalmic solution alone
seems to be insufficient. This is because the du-
ration of dacryocystitis is often longer than those
of other ocular infections; dacryocystitis is often
relapsing in nature; and surgical treatments, such
as dacryocystorhinostomy, are often necessary
for the treatment of this disease, as it can obstruct
the nasolacrimal duct.[21] As for the dosing fre-
quency of levofloxacin 0.5% ophthalmic solution,
it was higher in patients with bacterial corneal
ulcers than in patients with other ocular diseases.
This is because if corneal ulcers are aggravated,
visual disorders may occur. Because of this, the
Japanese guidelines on management of infectious
keratitis, which were made public in October
2007, recommend frequent application of anti-
microbial ophthalmic solution in patients with
severe infectious keratitis.[22] This study also
indicates that when treating bacterial corneal ul-
cers, treatment can be completed within 8 days in
half of all cases if levofloxacin 0.5% ophthalmic
solution is applied 4–6 times daily. Increasing the
frequency of dosing of levofloxacin 0.5% oph-
thalmic solution did not elevate the incidence of
ADRs.
Table VI. Rates of response to levofloxacin 0.5% ophthalmic sol-





Male 2 415 2318 [96.0]
Female 3 514 3342 [95.1]
Age <0.001b,c
<15 years 1 167 1142 [97.9]
<4 weeks 19 19 [100]
‡4 weeks and <1 year 178 173 [97.2]
‡1 and <7 years 622 612 [98.0]
‡7 and <15 years 348 338 [97.1]
‡15 and <65 years 2 788 2670 [95.8]
‡65 years 1 974 1848 [93.6]
Duration of illness <0.001b
1–2 days 2 692 2 603 [96.7]
3–4 days 1 213 1181 [97.4]
5–7 days 393 376 [95.7]
8–29 days 536 506 [94.4]
‡30 days 255 222 [87.1]
Unknown 840 772 [91.9]
First onset/relapse <0.001a
First onset 5 094 4917 [96.5]
Relapse 475 416 [87.6]
Unknown 360 327 [90.8]
a p-Values were assessed by Pearson’s w2 test. Cases with
unknown information were excluded from this test.
b p-Values were assessed by the Cochran-Armitage test. Cases
with unknown information were excluded from this test.
c p-Value for age <15 years versus ‡15 years and for age
<65 years versus ‡65 years.
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Conclusion
This post-marketing surveillance of levo-
floxacin 0.5% ophthalmic solution (Cravit
ophthalmic solution), conducted over 4 years,
confirms the safety and efficacy of levofloxacin
0.5% ophthalmic solution in regular clinical use
and highlights that it is a promising treatment for
a variety of external ocular bacterial infections.
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